Methods for treating pain
The present invention features methods and compositions for preventing, reducing, or treating a traumatic, metabolic or toxic peripheral nerve lesion or pain including, for example, neuropathic pain, inflammatory and nociceptive pain by administering to a mammal in need thereof a compound that reduces the expression or activity of BH4. According to this invention, this reduction may be achieved by reducing the enzyme activity of any of the BH4 synthetic enzymes, such as GTP cyclohydrolase (GTPCH), sepiapterin reductase (SPR), or dihydropteridine reductase (DHPR); by antagonizing the cofactor function of BH4 on BH4-dependent enzymes; or by blocking BH4 binding to membrane bound receptors. The compounds of the invention may be administered alone or in combination with a second therapeutic agent.
1. A method of treating or reducing pain in a mammal in need thereof, said method comprising administering to said mammal a composition comprising a compound having the formula:
R 1 is H, C 1-6 alkyl, halo, NO 2 , CN, CO 2 R 4 , CONR 4 R 5 , SO 2 R 4 , SO 2 NR 4 R 5 , OR 4 , or NR 4 R 5 , wherein each of R 4 and R 5 is, independently, H, C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl,
R 2 is H, C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl, and
R 3 is H, C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, C 1-4 alkheteroaryl, CO 2 R 6 , CONR 7 R 8 , SO 2 R 6 , or SO 2 NR 7 R 8 , wherein R 6 is C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl and each of R 7 and R 8 is, independently, H, C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl; or
R 3 is as above and R 1 and R 2 together are represented by
the N, O, or S of the R 1 /R 2 linkage forms a bond to the pyrimidinone ring and each of R 9 , R 10 , R 11 , R 12 , and R 13 is, independently, H, C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl; or
R 3 is as above and R 1 and R 2 together are represented by
wherein the N of the R 1 /R 2 linkage forms a bond to the pyrimidinone ring, each of R 12 and R 13 is as above, and R 14 is H, SH, OR 4 , halo, NO 2 , CN, CO 2 R 7 , CONR 7 R 8 , SO 2 R 7 , SO 2 NR 7 R 8 ,
C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl, wherein each of R 4 , R 7 and R 8 is, independently, H, C 1 -C 6 alkyl, C 6 -C 12 aryl, C 1 -C 4 alkaryl, heteroaryl, or C 1 -C 4 alkheteroaryl; or
R 1 and R 2 together are represented by
wherein the N of the R 1 /R 2 linkage forms a bond to the pyrimidinone ring, each of R 9 , R 10 , R 11 , and R 14 are as above, R 3 does not exist, and a double bond is formed between the carbon bearing R 14 and the nitrogen bearing R 2 ,
in an amount sufficient to result in a reduction of BH4 biological activity and thereby treat or reduce pain.
2. The method of claim 1 , wherein said mammal is a human.
3. The method of claim 1 , wherein the pain is reduced by reducing the BH4 levels in primary sensory neurons or dorsal horn neurons.
4. The method of claim 3 , wherein said primary sensory neurons are in a dorsal root ganglion or a trigeminal ganglion.
5. The method of claim 4 , wherein said dorsal horn neurons are in the spinal cord or spinal nucleus of the trigeminal in the brainstem.
6. The method of claim 1 , wherein the reduction in BH4 biological activity is the result of a reduction in BH4 synthesis or recycling.
7. The method of claim 1 , wherein said BH4 biological activity is reduced by increasing the expression, GTPCH-binding, or activity of GTP cyclohydrolase feedback regulatory protein (GFRP).
8. The method of claim 6 , wherein said reduction in BH4 synthesis is the result of a reduction in the level or biological activity of at least one enzyme selected from the group consisting of sepiapterin reductase (SPR), Pyruvoyltetrahydropterin Synthase (PTPS), GTP cyclohydrolase (GTPCH), Pterin-4α-carbinolamine dehydratase, and dihydropteridine reductase (DHPR).
9. The method of claim 8 , wherein said reduction in BH4 synthesis is the result of a reduction in the biological activity of at least one enzyme selected from the group consisting of sepiapterin reductase (SPR), GTP cyclohydrolase (GTPCH), and dihydropteridine reductase (DHPR).
10. The method of claim 8 , wherein the biological activity of at least two of said enzymes is reduced.
11. The method of claim 10 , wherein the biological activity of at least three of said enzymes is reduced.
12. The method of claim 8 , wherein said biological activity is reduced by at least 10%.
13. The method of claim 12 , wherein said biological activity is reduced by at least 40%.
14. The method of claim 1 , wherein said composition comprises a compound of formula (I), wherein
R 1 is H, C 1-6 alkyl, halo, NO 2 , CN, CO 2 R 4 , CONR 4 R 5 , SO 2 R 4 , SO 2 NR 4 R 5 , OR 4 , or NR 4 R 5 , wherein each of R 4 and R 5 is, independently, H, C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl,
R 2 is H, C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl, and
R 3 is H, C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, C 1-4 alkheteroaryl, CO 2 R 6 , CONR 7 R 8 , SO 2 R 6 , or SO 2 NR 7 R 8 , wherein R 6 is C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl and each of R 7 and R 8 is, independently, H, C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl.
15. The method of claim 1 , wherein said composition comprises a compound of formula:
R 1 and R 2 together are represented by
the N, O, or S of the R 1 /R 2 linkage forms a bond to the pyrimidinone ring and each of R 9 , R 10 , R 11 , R 12 , and R 13 is, independently, H, C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl, and
R 3 is H, C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, C 1-4 alkheteroaryl, CO 2 R 6 , CONR 7 R 8 , SO 2 R 6 , or SO 2 NR 7 R 8 , wherein R 6 is C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl and each of R 7 and R 8 is, independently, H, C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl.
16. The method of claim 1 , wherein said composition comprises a compound of formula:
R 1 and R 2 together are represented by
wherein the N of the R 1 /R 2 linkage forms a bond to the pyrimidinone ring,
R 3 is H, C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, C 1-4 alkheteroaryl, CO 2 R 6 , CONR 7 R 8 , SO 2 R 6 , or SO 2 NR 7 R 8 , wherein R 6 is C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl,
each of R 12 and R 13 is, independently, H, C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl,
R 14 is H, SH, OR 4 , halo, NO 2 , CN, CO 2 R 7 , CONR 7 R 8 , SO 2 R 7 , SO 2 NR 7 R 8 ,
C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl,
wherein each of R 4 , R 7 , and R 8 is, independently, H, C 1 -C 6 alkyl, C 6 -C 12 aryl, C 1 -C 4 alkaryl, heteroaryl, or C 1 -C 4 alkheteroaryl.
17. The method of claim 1 , wherein said composition comprises a compound of formula:
R 1 and R 2 together are represented by
wherein the N of the R 1 /R 2 linkage forms a bond to the pyrimidinone ring,
each of R 9 , R 10 , and R 11 is, independently, H, C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl,
R 14 is H, SH, OR 4 , halo, NO 2 , CN, CO 2 R 7 , CONR 7 R 8 , SO 2 R 7 , SO 2 NR 7 R 8 ,
C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl, wherein each of R 4 , R 7 , and R 8 is, independently, H, C 1-6 alkyl, C 6-12 aryl, C 1-4 alkaryl, heteroaryl, or C 1-4 alkheteroaryl,
R 3 does not exist, and a double bond is formed between the carbon bearing R 14 and the nitrogen bearing R 2 .
18. The method of claim 14 , wherein said composition comprises a compound selected from the group consisting of
19. The method of claim 1 , wherein said pain is acute pain.
20. The method of claim 1 , wherein said pain is chronic pain.
21. The method of claim 1 , wherein said pain is selected from the group consisting of peripheral and central neuropathic pain, inflammatory pain, functional pain, nociceptive pain, and headache.
22. The method of claim 21 , wherein said pain is neuropathic pain.
23. The method of claim 21 , wherein said pain is inflammatory pain.
24. The method of claim 1 , wherein said pain is a caused by peripheral nerve damage or a peripheral nerve lesion.
25. A method of treating or reducing pain in a mammal in need thereof, said method comprising administering to said mammal a composition comprising a compound having the formula:
R 1 is H, C 1-6 alkyl, halo, NO 2 , CN, CO 2 R 4 , CONR 4 R 5 , SO 2 R 4 , SO 2 NR 4 R 5 , OR 4 , or NR 4 R 5 , wherein each of R 4 and R 5 is, independently, H, C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl,
R 2 is H, C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl, and
R 3 is H, C 1-6 alkyl, C 6-12 aryl, C 1-4 alkaryl, CO 2 R 6 , CONR 7 R 8 , SO 2 R 6 , or SO 2 NR 7 R 8 , wherein R 6 is C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl and each of R 7 and R 8 is, independently, H, C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl; or
R 3 is as above and R 1 and R 2 together are represented by
the N, O, or S of the R 1 /R 2 linkage forms a bond to the pyrimidinone ring and each of R 9 , R 10 , R 11 , R 12 and R 13 is, independently, H, C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl; or
R 3 is as above and R 1 and R 2 together are represented by
wherein the N of the R 1 /R 2 linkage forms a bond to the pyrimidinone ring, each of R 12 and R 13 is as above, and R 14 is H, SH, OR 4 , halo, NO 2 , CN, CO 2 R 7 , CONR 7 R 8 , SO 2 R 7 , SO 2 NR 7 R 8 ,
C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl, wherein each of R 4 , R 7 and R 8 is, independently, H, C 1 -C 6 alkyl, C 6 -C 12 aryl, C 1 -C 4 alkaryl, heteroaryl, or C 1 -C 4 alkheteroaryl; or
R 1 and R 2 together are represented by
wherein the N of the R 1 /R 2 linkage forms a bond to the pyrimidinone ring, each of R 9 , R 10 , R 11 , and R 14 are as above, R 3 does not exist, and a double bond is formed between the carbon bearing R 14 and the nitrogen bearing R 2 ,
in an amount sufficient to treat or reduce pain.
26. The method of claim 25 , wherein said composition comprises a compound of formula (I), wherein
R 1 is H, C 1-6 alkyl, halo, NO 2 , CN, CO 2 R 4 , CONR 4 R 5 , SO 2 R 4 , SO 2 NR 4 R 5 , OR 4 , or NR 4 R 5 , wherein each of R 4 and R 5 is, independently, H, C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl,
R 2 is H, C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl, and
R 3 is H, C 1-6 alkyl, C 6-12 aryl, C 1-4 alkaryl, CO 2 R 6 , CONR 7 R 8 , SO 2 R 6 , or SO 2 NR 7 R 8 , wherein R 6 is C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl and each of R 7 and R 8 is, independently, H, C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl.
27. The method of claim 25 , wherein said composition comprises a compound of formula:
R 1 and R 2 together are represented by
the N, O, or S of the R 1 /R 2 linkage forms a bond to the pyrimidinone ring and each of R 9 , R 10 , R 11 , R 12 , and R 13 is, independently, H, C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl, and
R 3 is H, C 1-6 alkyl, C 6-12 aryl, C 1-4 alkaryl, CO 2 R 6 , CONR 7 R 8 , SO 2 R 6 , or SO 2 NR 7 R 8 , wherein R 6 is C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl and each of R 7 and R 8 is, independently, H, C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl.
28. The method of claim 25 , wherein said composition comprises a compound of formula:
R 1 and R 2 together are represented by
wherein the N of the R 1 /R 2 linkage forms a bond to the pyrimidinone ring,
R 3 is H, C 1-6 alkyl, C 6-12 aryl, C 1-4 alkaryl, CO 2 R 6 , CONR 7 R 8 , SO 2 R 6 , or SO 2 NR 7 R 8 , wherein R 6 is C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl,
each of R 12 and R 13 is, independently, H, C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl,
R 14 is H, SH, OR 4 , halo, NO 2 , CN, CO 2 R 7 , CONR 7 R 8 , SO 2 R 7 , SO 2 NR 7 R 8 ,
C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl,
wherein each of R 4 , R 7 , and R 8 is, independently, H, C 1 -C 6 alkyl, C 6 -C 12 aryl, C 1 -C 4 alkaryl, heteroaryl, or C 1 -C 4 alkheteroaryl.
29. The method of claim 25 , wherein said composition comprises a compound of formula:
R 1 and R 2 together are represented by
wherein the N of the R 1 /R 2 linkage forms a bond to the pyrimidinone ring,
each of R 9 , R 10 , and R 11 is, independently, H, C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl,
R 14 is H, SH, OR 4 , halo, NO 2 , CN, CO 2 R 7 , CONR 7 R 8 , SO 2 R 7 , SO 2 NR 7 R 8 ,
C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl, wherein each of R 4 , R 7 , and R 8 is, independently, H, C 1-6 alkyl, C 6-12 aryl, C 1-4 alkaryl, heteroaryl, or C 1-4 alkheteroaryl,
R 3 does not exist, and a double bond is formed between the carbon bearing R 14 and the nitrogen bearing R 2 .
30. The method of claim 1 , wherein said composition comprises a compound of formula:
R 1 and R 2 together are represented by
the N, O, or S of the R 1 /R 2 linkage forms a bond to the pyrimidinone ring and each of R 9 , R 10 , R 11 , R 12 , and R 13 is, independently, H, C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl.
31. The method of claim 25 , wherein said composition comprises a compound of formula:
R 3 is as above and R 1 and R 2 together are represented by
wherein the N of the R 1 /R 2 linkage forms a bond to the pyrimidinone ring,
each of R 12 and R 13 is, independently, H, C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl, and
R 14 is H, SH, OR 4 , halo, NO 2 , CN, CO 2 R 7 , CONR 7 R 8 , SO 2 R 7 , SO 2 NR 7 R 8 ,
C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl, wherein each of R 4 , R 7 and R 8 is, independently, H, C 1 -C 6 alkyl, C 6 -C 12 aryl, C 1 -C 4 alkaryl, heteroaryl, or C 1 -C 4 alkheteroaryl.
32. The method of claim 25 , wherein said composition comprises a compound of formula:
R 1 and R 2 together are represented by
wherein the N of the R 1 /R 2 linkage forms a bond to the pyrimidinone ring,
each of R 9 , R 10 , and R 11 is, independently, H, C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl, and
R 14 is H, SH, OR 4 , halo, NO 2 , CN, CO 2 R 7 , CONR 7 R 8 , SO 2 R 7 , SO 2 NR 7 R 8 ,
C 1-6 alkyl, C 6-12 aryl, heteroaryl, C 1-4 alkaryl, or C 1-4 alkheteroaryl, wherein each of R 4 , R 7 and R 8 is, independently, H, C 1-6 alkyl, C 6-12 aryl, C 1-4 alkaryl, heteroaryl, or C 1-4 alkheteroaryl,
R 3 does not exist, and a double bond is formed between the carbon bearing R 14 and the nitrogen bearing R 2 .
33. The method of claim 26 , wherein said composition comprises a compound selected from the group consisting of
34. The method of claim 25 , wherein said pain is acute pain.
35. The method of claim 25 , wherein said pain is chronic pain.
36. The method of claim 25 , wherein said pain is selected from the group consisting of peripheral and central neuropathic pain, inflammatory pain, functional pain, nociceptive pain, and headache.
37. The method of claim 36 , wherein said pain is neuropathic pain.
38. The method of claim 36 , wherein said pain is inflammatory pain.
39. The method of claim 25 , wherein said pain is a caused by peripheral nerve damage or a peripheral nerve lesion.